The Emerging Role of β-Lactams in the Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections
Kyle C. Molina, Taylor Morrisette, Matthew A. Miller, Vanthida Huang, Douglas N. Fish
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI) are associated with substantial morbidity and mortality. Monotherapy with first-line antimicrobials such as vancomycin (VAN; glycopeptide) and daptomycin (DAP; lipopeptide) are inadequate in some cases due to reduced antibiotic susceptibilities or therapeutic failure. In recent years, β-lactam antibiotics have emerged as a potential option for combination therapy with VAN and DAP that may meet an unmet therapeutic need for MRSA BSI.
Topics & Concepts
DaptomycinStaphylococcus aureusMethicillin-resistant Staphylococcus aureusMedicineAntibioticsVancomycinMicrobiologyGlycopeptideStaphylococcal infectionsLipopeptideBacteremiaTeicoplaninBloodstream infectionIntensive care medicineBiologyBacteriaGeneticsAntimicrobial Resistance in StaphylococcusAntibiotics Pharmacokinetics and EfficacyBacterial Identification and Susceptibility Testing